PunchS’West APC youths name advisory council chairThe Jerusalem PostPolice recover antique Torah scroll case stolen from Jerusalem synagogue over 20 years ago한겨레‘수능 7등급’ 감스트 “AI 안경 쓰니 수학 5개 틀려”InquirerQC orders midnight closure of bars, karaoke venues for Nov. 15 to 21ZDF heuteAktuelle Pressemitteilungen des ZDFDaily MaverickRocket from Boeing-Lockheed firm fails mid-flight, destroys payload of Amazon satellitesStraits Times SportF1 must push harder, move faster to open up motorsport careers, says HamiltonMalay MailMusk, tech leaders join 158,000 calling for Jensen Huang’s return; 7,500 are Nvidia staffThe Sydney Morning HeraldBeau Lamarre-Condon trial live updates: Alleged double murderer, NSW Police officer’s re-examination beginsLenta.ruРаскрыто наполнение будущего пакета антироссийских санкций ЕСLa TerceraTras el descenso a Segunda División: vandalizan la Fortaleza Rojinegra, el complejo deportivo de RangersNew Straits TimesF1 must push harder, move faster to open up motorsport careers
The Daily Newsstand · Free, Always
Monday, November 16, 2026

焦點股》浩鼎:ADC平台 授權國際大藥廠諾華

Translate

〔記者陳永吉/台北報導〕台灣浩鼎生技(4174)上週五宣布與國際大藥廠諾華(Novartis Pharma AG)簽署合作暨授權協議,諾華將運用浩鼎多項專有抗體藥物複合體(Antibody-Drug Conjugate, ADC)平台技術,開發搭載新型藥物載荷(payload)的次世代ADC藥物。浩鼎將獲得3000萬美元(約新台幣9.8億元)的簽約金,並有機會依後續研發、法規核准及商業化進展取得階段性里程碑付款,總潛在交易價值超過20億美元。

浩鼎今股價在此利多消息激勵下跳空漲停,來到71.3元,創下今年2月減資掛牌後新高價,截至9:12分為止,浩鼎股價緊鎖漲停,成交量135張,漲停委買張數達8.8萬張。

這項合作對研發新藥多年的浩鼎無疑是一項營運強心針,也終於在浩鼎案後繳出可以對股東交代的成績單,雖然簽約金僅不到10億元,但對象是國際前幾大藥廠,跟之前台灣生技業者簽約對象多是中小型藥廠有明顯不同,顯示浩鼎研發成果終被大廠認同,對國內生技業具有指標意義。

View the original on 自由時報 →

KioskNews shows a cleaned-up reading view extracted from the publisher’s page — the original always lives on their site, not ours.